E N D
Supplemental Digital Content 2- Figure 2.Synergism achieved by combining HP-OVA with RTIs for inhibition of infection by HIV-1IIIB (A-C) and HIV-1BaL (D-F). (A) HP-OVA and Tenofovir; (B) HP-OVA and UC781; (C) HP-OVA and TMC120; (D) HP-OVA and Tenofovir; (E) HP-OVA and UC781 and (F) HP-OVA and TMC120. Inhibitory activity on p24 production was detected by ELISA. Each sample was tested in triplicate, and the data are presented as means ± SD.